CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PharmaTimes
Original article

Lexeo wins FDA RMAT status for LX2020

RegulatorypositiveLX2020Positive
AI Analysis

Summary

Lexeo announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) status for LX2020, a gene therapy candidate for PKP2-associated cardiomyopathy.

Outcome Details

FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation

Importance:7/10
Sentiment:
0.80
gene therapyRMAT designationFDAPKP2-ACMregulatory milestone
Related Companies

Read the original article

Published by PharmaTimes on August 3, 2026 10:32 PM

Read Original